<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720886</url>
  </required_header>
  <id_info>
    <org_study_id>G56W1A201</org_study_id>
    <nct_id>NCT03720886</nct_id>
  </id_info>
  <brief_title>G56W1 in Women With Postmenopausal Osteoporosis</brief_title>
  <official_title>Two-dose, Positive Drug Control, Multicentre, Randomized, Double-blind Study of Recombinant Human Parathyroid Hormone for Injection(rhPTH)(1-34) Once a Week to Treat Postmenopausal Osteoporosis Women for the Evaluation the Pharmacokinetics and Safety and to Explore Therapeutic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Salubris Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Salubris Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics and safety and explore therapeutic effects with&#xD;
      once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women&#xD;
      with post-menopausal osteoporosis .The anticipated time on study treatment is 24 weeks, and&#xD;
      the target sample size is 148 individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage change in bone density of the lumbar spine ( L1-4 ) from baseline to 24 weeks after treatment</measure>
    <time_frame>Baseline，week 24</time_frame>
    <description>bone mineral density(BMD) measured by dual energy x-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the rate of change of Procollagen I N-terminal peptide(PINP),Serum cross-linked C-terminal telopeptide of type I collagen(s-CTX) ,Bone alkaline phosphatase(BALP) , and blood calcium from baseline</measure>
    <time_frame>Baseline，week 24</time_frame>
    <description>Central lab will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage change of total hip bone density from baseline to 24 weeks after G56W1 treatment</measure>
    <time_frame>Baseline，week 24</time_frame>
    <description>BMD measured by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum parathyroid hormone(PTH) will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum PTH will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration（Tmax）</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum PTH will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life（t1/2）</measure>
    <time_frame>Baseline，week 1，week 4，week 12，week 24</time_frame>
    <description>serum PTH will be tested for all pharmacokinetics parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>rhPTH（1-34） 28.2μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhPTH（1-34） 56.5μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide acetate(Teribone™)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rhPTH（1-34） 28.2μg</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>rhPTH（1-34） 28.2μg</arm_group_label>
    <other_name>G56W1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rhPTH（1-34） 56.5μg</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>rhPTH（1-34） 56.5μg</arm_group_label>
    <other_name>G56W1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>teriparatide acetate(Teribone™)</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>teriparatide acetate(Teribone™)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, capable of self - motivation , 45 years old ≤ age ≤ 75 years old.&#xD;
&#xD;
          -  Natural menopause for 3 years or more; or surgical menopause for 3 years or more&#xD;
             (surgery needs to be performed after 40 years old), for women with surgical menopause,&#xD;
             estradiol(E2)&lt; 25 pg/ml and follicle stimulating hormone(FSH) &gt; 40mIU/ml should be&#xD;
             met.&#xD;
&#xD;
          -  Weight ≥ 40kg , 18 ≤ body mass index(BMI)≤ 30 .&#xD;
&#xD;
          -  Meets one of the following diagnostic criteria for osteoporosis, and ≥ 3 vertebral&#xD;
             bodies of L1-4 can be measured by bone mineral density using the DXA method.&#xD;
&#xD;
               1. Brittle fracture of the hip or vertebral body, and the bone density measurement&#xD;
                  T- score&lt; -1.0.&#xD;
&#xD;
               2. The T- score of the central axis bone mineral density or the 1/3 bone density of&#xD;
                  the distal radius of the tibia was ≤-2.5 measured by DXA .&#xD;
&#xD;
               3. Bone density measurements were consistent with low bone mass ( -2.5 &lt; T- value &lt;&#xD;
                  -1.0 ) and combined with proximal humerus, pelvic or forearm distal brittle&#xD;
                  fractures.&#xD;
&#xD;
          -  to participate in the trial and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  to have diseases affecting calcium or bone metabolism that are not effectively&#xD;
             controlled, such as primary hyperparathyroidism or hyperthyroidism, Paget's bone&#xD;
             disease, hypercalcemia, hypocalcemia, active urolithiasis.&#xD;
&#xD;
          -  Secondary osteoporosis, such as osteomalacia, rheumatoid arthritis, gout, multiple&#xD;
             myeloma, etc.&#xD;
&#xD;
          -  Severe lumbar anatomical abnormalities which affecting DXA bone mineral density&#xD;
             measurement, such as severe scoliosis.&#xD;
&#xD;
          -  Patients who have been treated for anti-osteoporosis before random enrollment:&#xD;
&#xD;
               1. Patients who received parathyroid hormone(PTH) therapy before random enrollment&#xD;
                  (including clinical trials of similar products).&#xD;
&#xD;
               2. Patients who received bisphosphonate injection within 1 year prior to random&#xD;
                  enrollment or received bisphosphonate oral administration within 3 months for &gt; 2&#xD;
                  weeks prior to enrollment.&#xD;
&#xD;
               3. Systemic treatment of androgen, estrogen, and selective estrogen receptor&#xD;
                  modulator(SERM) preparations within 3 months &gt; 2 weeks prior to random&#xD;
                  enrollment.&#xD;
&#xD;
               4. Three months before randomized to receive of heparin, warfarin, anticonvulsants&#xD;
                  (except benzodiazepines), digoxin accumulated for&gt; 2 weeks.&#xD;
&#xD;
               5. In the 3 months prior to random enrollment , received calcitonin, vitamin K&#xD;
                  preparation, active vitamin D3 preparation, oral or intravenous glucocorticoid&#xD;
                  treatment for &gt; 4 weeks.&#xD;
&#xD;
          -  Suffering from severe kidney disease, uncontrolled high blood pressure ( ≥150/100 mmHg&#xD;
             ), symptomatic ischemic heart disease, cerebral infarction or obliterative&#xD;
             atherosclerosis, malignancy, and other serious underlying diseases.&#xD;
&#xD;
          -  Laboratory tests indicates abnormal, including any of the following indicators&#xD;
             abnormalities (according to the normal range of each center, after consideration of&#xD;
             the investigator with clinical considerations, such as caused by operational&#xD;
             procedures, etc., after discussion with the sponsor, may allow retesting once) .&#xD;
&#xD;
               1. Alkaline phosphatase(ALP)&gt;1.5 times the upper limit of normal.&#xD;
&#xD;
               2. Aspartate transaminase(AST) or alanine aminotransferase(ALT) or total&#xD;
                  bilirubin(TBIL) &gt; 2.0 times the upper limit of normal.&#xD;
&#xD;
               3. Glycated hemoglobin(HbA1c )≥ 7.0% .&#xD;
&#xD;
               4. White blood cell(WBC)&lt; 3.5×10^9 /L , Hb&lt;100g/L or Plt&lt;90×10^9 /L.&#xD;
&#xD;
               5. Thyroid-stimulating hormone(TSH)&lt;0.01 mIU/L (mU/L) or TSH&gt;10 mIU/L (mU/L) .&#xD;
&#xD;
               6. Parathyroid hormone(PTH)&gt;1.5 times the upper limit of normal.&#xD;
&#xD;
               7. Serum creatinine(SCr)&gt;1.2 times the upper limit of normal.&#xD;
&#xD;
               8. Serum total calcium(SCa)&gt; normal upper limit.&#xD;
&#xD;
          -  Subjects who had significant clinical significance including HIV , hepatitis B,&#xD;
             hepatitis C, and syphilis ( hepatitis B virus carriers can be enrolled ) .&#xD;
&#xD;
          -  Heavy Smoking (average of more than 10 / day) and / or alcohol addicted (converted to&#xD;
             pure alcohol 30 ml / day or more) .&#xD;
&#xD;
          -  Recent drug abuse or drug dependence evidence.&#xD;
&#xD;
          -  Those who are allergic to test drugs / control drugs or biological products.&#xD;
&#xD;
          -  Included in other interventional clinical trials within 3 months of the study.&#xD;
&#xD;
          -  Been undergone radiation therapy for bones.&#xD;
&#xD;
          -  Mental illness or any cause of cognitive impairment.&#xD;
&#xD;
          -  Patients who were considered unsuitable for the study based on risk benefits by&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weibo Xia, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Wanzhou</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West China Second UniversityHospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

